Coloplast (COLO B) Stock Overview
Engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
COLO B Community Fair Values
Create NarrativeSee what 25 others think this stock is worth. Follow their fair value or set your own to get alerts.
Coloplast A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 585.60 |
| 52 Week High | DKK 934.60 |
| 52 Week Low | DKK 540.80 |
| Beta | 0.53 |
| 1 Month Change | -1.15% |
| 3 Month Change | -3.56% |
| 1 Year Change | -35.45% |
| 3 Year Change | -30.22% |
| 5 Year Change | -38.91% |
| Change since IPO | 4,482.96% |
Recent News & Updates
Recent updates
Coloplast A/S Just Missed EPS By 16%: Here's What Analysts Think Will Happen Next
Aug 22
Investors Still Waiting For A Pull Back In Coloplast A/S (CPH:COLO B)
May 25Does Coloplast (CPH:COLO B) Have A Healthy Balance Sheet?
May 06Are Investors Undervaluing Coloplast A/S (CPH:COLO B) By 35%?
Apr 18Coloplast A/S' (CPH:COLO B) Share Price Could Signal Some Risk
Jan 27An Intrinsic Calculation For Coloplast A/S (CPH:COLO B) Suggests It's 47% Undervalued
Jan 09Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's
Dec 04Should Shareholders Have Second Thoughts About A Pay Rise For Coloplast A/S' (CPH:COLO B) CEO This Year?
Nov 29Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's
Nov 13Earnings Update: Coloplast A/S (CPH:COLO B) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts
Nov 08
Operational Efficiencies And Innovations In Urology And Wound Care Propel Future Growth
Improved operational efficiency and strategic expansions are expected to enhance net margins and earnings over the long term.Shareholder Returns
| COLO B | DK Medical Equipment | DK Market | |
|---|---|---|---|
| 7D | 2.7% | 3.0% | -2.5% |
| 1Y | -35.4% | -28.0% | -37.9% |
Return vs Industry: COLO B underperformed the Danish Medical Equipment industry which returned -28% over the past year.
Return vs Market: COLO B exceeded the Danish Market which returned -37.9% over the past year.
Price Volatility
| COLO B volatility | |
|---|---|
| COLO B Average Weekly Movement | 3.3% |
| Medical Equipment Industry Average Movement | 5.0% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in DK Market | 8.6% |
| 10% least volatile stocks in DK Market | 2.5% |
Stable Share Price: COLO B has not had significant price volatility in the past 3 months compared to the Danish market.
Volatility Over Time: COLO B's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1954 | 16,814 | n/a | www.coloplast.com |
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand.
Coloplast A/S Fundamentals Summary
| COLO B fundamental statistics | |
|---|---|
| Market cap | DKK 131.86b |
| Earnings (TTM) | DKK 4.08b |
| Revenue (TTM) | DKK 27.87b |
Is COLO B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COLO B income statement (TTM) | |
|---|---|
| Revenue | DKK 27.87b |
| Cost of Revenue | DKK 9.04b |
| Gross Profit | DKK 18.82b |
| Other Expenses | DKK 14.75b |
| Earnings | DKK 4.08b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 04, 2025
| Earnings per share (EPS) | 18.10 |
| Gross Margin | 67.55% |
| Net Profit Margin | 14.62% |
| Debt/Equity Ratio | 141.3% |
How did COLO B perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/20 04:21 |
| End of Day Share Price | 2025/10/17 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Coloplast A/S is covered by 45 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Robert Bate | Barclays |
| Hassan Al-Wakeel | Barclays |